Corrigendum to "Impact of heart failure severity and major bleeding events after percutaneous coronary intervention on subsequent major adverse cardiac events" [Int. J. Cardiol. Cardiovasc. Risk and Prev. 2023 Jun 25:18:200193]

Affiliations

¹ Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
² Department of Medical Information Science, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
³ Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
⁴ Department of Clinical Informatics, Jichi Medical University School of Medicine, Tochigi, Japan.
⁵ Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
⁶ Division of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Tochigi, Japan.
⁷ Department of Cardiovascular Medicine, The University of Tokyo Hospital, Tokyo, Japan.
⁸ Development Bank of Japan Inc., Tokyo, Japan.
⁹ Division of Cardiovascular Medicine, Tohoku University Hospital, Sendai, Japan.
¹⁰ Department of Medical Informatics, Tohoku University Graduate School of Medicine, Miyagi, Japan.
¹¹ Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
¹² Open Innovation Center, National Cerebral and Cardiovascular Center, Osaka, Japan.
¹³ Precision Inc., Tokyo, Japan.
¹⁴ Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
¹⁵ Jichi Medical University School of Medicine, Tochigi, Japan.

Published Erratum

So Ikebe et al. Int J Cardiol Cardiovasc Risk Prev. 2024.

. 2024 Jul 5:22:200304.

doi: 10.1016/j.ijcrp.2024.200304. eCollection 2024 Sep.

¹ Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
² Department of Medical Information Science, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
³ Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
⁴ Department of Clinical Informatics, Jichi Medical University School of Medicine, Tochigi, Japan.
⁵ Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
⁶ Division of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Tochigi, Japan.
⁷ Department of Cardiovascular Medicine, The University of Tokyo Hospital, Tokyo, Japan.
⁸ Development Bank of Japan Inc., Tokyo, Japan.
⁹ Division of Cardiovascular Medicine, Tohoku University Hospital, Sendai, Japan.
¹⁰ Department of Medical Informatics, Tohoku University Graduate School of Medicine, Miyagi, Japan.
¹¹ Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
¹² Open Innovation Center, National Cerebral and Cardiovascular Center, Osaka, Japan.
¹³ Precision Inc., Tokyo, Japan.
¹⁴ Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
¹⁵ Jichi Medical University School of Medicine, Tochigi, Japan.

Abstract

[This corrects the article DOI: 10.1016/j.ijcrp.2023.200193.].

Impact of heart failure severity and major bleeding events after percutaneous coronary intervention on subsequent major adverse cardiac events.
Ikebe S, Ishii M, Otsuka Y, Nakamura T, Tsujita K, Matoba T, Kohro T, Oba Y, Kabutoya T, Imai Y, Kario K, Kiyosue A, Mizuno Y, Nochioka K, Nakayama M, Iwai T, Miyamoto Y, Sato H, Akashi N, Fujita H, Nagai R; CLIDAS research group. Ikebe S, et al. Int J Cardiol Cardiovasc Risk Prev. 2023 Jun 25;18:200193. doi: 10.1016/j.ijcrp.2023.200193. eCollection 2023 Sep. Int J Cardiol Cardiovasc Risk Prev. 2023. PMID: 37415925 Free PMC article.